A Study to Assess the Relative Bioavailability and Food Effect of ABI-H2158 in Healthy Adults

• Status: Completed
• Trial end date: 2019-10-07
• Target enrollment: 0
• Participant gender: All

Summary

This study is designed to assess the relative bioavailability of ABI-H2158 tablets (Test Formulation) compared to ABI-H2158 tablets (Reference Formulation). The effect of food on the pharmacokinetics of the Test Formulation will also be evaluated under fed and fasting conditions.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Assembly Biosciences

Criteria

Inclusion Criteria:

1. No clinically significant abnormal findings on physical exam, medical history, or clinical laboratory results at screening.

Exclusion Criteria:

1. Positive test results for human immunodeficiency virus (HIV) or hepatitis B or C.

2. Treatment for drug or alcohol dependence.